ABL1 and acute lymphoblastic leukemia: In addition to treatment resistance, the high degree of relapse observed in BCR-ABL1-like patients and, more importantly, those who were MRD-negative at the end of induction, suggests that standard treatments are not less efficient for this ALL subtype.